Reprint
Rheumatoid Arthritis Therapy Reappraisal
Strategies, Opportunities and Challenges
Edited by
September 2020
260 pages
- ISBN978-3-03943-090-1 (Hardback)
- ISBN978-3-03943-091-8 (PDF)
This book is a reprint of the Special Issue Rheumatoid Arthritis Therapy Reappraisal: Strategies, Opportunities and Challenges that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes of drugs have shown to halt disease progression in clinical studies. In real life, a physician has more options than just adding or switching to a new ts/bDMARD if any kind of DMARDs has failed. They can modify or optimize the therapy with concomitant csDMARDs, and oral or IA-GC can be added to the treatment regimen. The EULAR states that therapeutic adjustment including the "optimization of csDMARDs dose or route of administration or intra-articular injections of GCs" is recommended. Thus, a new therapeutic agent can be embedded in a whole strategy with parallel optimization of the csDMARD and GC treatment. The idea of treating to target (T2T) for the treatment of RA patients has been around since the late 1990s. Many clinical studies (Ticora, BsSt, Camera) have demonstrated the superiority of a T2T approach. When I talk to physicians, I understand that most of them only rarely inject joints with GC. Therefore, I would like to create an issue on the T2T approach in reality including primary data, reviews, and real-life data demonstrating the general opinion and execution of T2T in treating RA.
Format
- Hardback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
rheumatoid arthritis; sleep; sleep disorders; pain; osteoporosis; fracture; fracture risk assessment tool; rheumatoid arthritis; rheumatoid arthritis; treat-to-target; certolizumab pegol; csDMARDs; glucocorticoids; intra-articular injections; DAS 28; ACR response; HAQ-DI; rheumatoid arthritis; TNFα; golimumab; efficacy; tolerability; immunogenicity; methotrexate; rheumatoid arthritis; tolerability; efficacy; posology; titration; oral route; subcutaneous route; bioavailability; effectiveness; rheumatoid arthritis; periodontitis; periodontal disease; anti-citrullinated protein autoantibodies; rheumatoid factor; smoking; medication; Porphyromonas gingivalis; Rheumatoid arthritis; Porphyromonas gingivalis; periodontal disease; matrix metalloproteinase 3; infliximab; rheumatoid arthritis; pharmacogenomics; methotrexate; anti-TNF; personalized medicine; baricitinib; disease-modifying antirheumatic drugs; pain perception; outcomes research; patient perspective; rheumatoid arthritis; Rheumatoid Arthritis; therapy; DMARD; MTX; Tumor Necrosis Factor-Alpha Inhibitors; ankylosing spondylitis; infliximab; biosimilar; switching; rheumatoid arthritis; synovial fibroblasts; cytokine; osteoclast; herbal medicine; rheumatoid arthritis; methylation; next-generation sequencing; rheumatoid arthritis; baricitinib; pain; recovery of function; fatigue; productivity; tofacitinib; rheumatoid arthritis; oral; Th1.17; IL-17A; IFN-γ, CD73; adenosine; rheumatoid arthritis; psoriatic arthritis; methotrexate; regulation; rheumatoid arthritis; pseudoerosions; hand; foot; ultrasonography; radiography; computed tomography; magnetic resonance imaging; n/a